arrow
M

Matteo Lazzeroni

European Institute of Oncology
H指数:27
被引数:2,600

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SHBG as a breast cancer risk biomarker in premenopausal women? Results from an individual patient's pooled analysis and a meta-analysis

性激素结合球蛋白作为绝经前女性乳腺癌风险生物标志物?个体患者合并分析及荟萃分析的结果

2026-09-110
OAAI
Artificial intelligence for risk-stratified breast cancer screening: a systematic review of evidence, clinical integration, and ethical implications in risk assessment tools

人工智能用于风险分层的乳腺癌筛查:对证据、临床整合和风险评估工具中伦理影响的系统综述

2026-05-180
PRE
Anti-IL5/IL-5 receptor therapies for eosinophilic granulomatosis with polyangiitis: an updated Systematic Review

抗IL5/IL-5受体疗法在嗜酸性肉芽肿性多血管炎中的应用:一项更新的系统综述

2025-07-220
OA
Germline Testing in Breast Cancer: A Single-Center Analysis Comparing Strengths and Challenges of Different Approaches

乳腺癌中的胚系检测:一项比较不同方法的优势与挑战的单中心分析

CANCERS
IF4.4
2025-04-240
OA
Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules
2024-08-070
PRE
Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ

乳腺导管原位癌患者免疫相关基因表达与乳腺癌复发的关系

2024-05-010
OA
Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation
2024-01-181
OA
10-year results of a phase 3 trial of low-dose tamoxifen in non-invasive breast cancer
2023-03-011
PRE
Diagnostic performance of image-guided vacuum-assisted breast biopsy after neoadjuvant therapy for breast cancer: prospective pilot study
2022-12-077
OAAI
Advances and controversies in management of breast ductal carcinoma in situ (DCIS)
EJSO
IF2.9
2022-04-0118
PRE